29 November 2019
Visiongain has launched a new pharma report ‘’North America and Europe Stroke Diagnostics Market Report 2020-2030’’ by Technology (Carotid Ultrasound, Cerebral Angiography, Computed Tomography Scan, Magnetic Resonance Imaging, Nuclear Imaging, Others), and Geography.
North America and Europe's stroke diagnostics market is anticipated to grow at a lucrative CAGR of 6.6% and anticipated to reach USD 3.24 Billion by 2030.
Stroke is considered one of North America's and Europe's leading causes of death and physical disability. The growing geriatric population is expected to intensify the need for rapid diagnosis of disease. According to the UN, 27 percent of Germany's population is over 60 years of age. It is projected that this number will grow by 39 percent by 2050.
The risk of stroke has tripled by unhealthy lifestyle patterns. Obesity, physical inactivity, elevated stress at work and in life, and excessive alcohol and tobacco use are the most common factors. The noxious factors that can contribute to stroke are unhealthy diets that include saturated fats, trans-fats, and cholesterol. The prevalence of unhealthy lifestyle is likely to lead to such diseases, which are expected to drive the development of the industry shortly.
Improved understanding of early signs of stroke and its causes is expected to have a positive influence over the forecast period on consumer growth. U.S. government and other such programs are expected to introduce smoking cessation to raise demand for stroke treatment shortly.
Stroke prevalence is decreasing rapidly in regions such as the United States. France recorded the lowest number of stroke-related deaths among all European nations, 5.7% compared to 6.5% in Germany and 9.7% in Italy in 2013. The fall is also due to the reduction of smoking and the availability of improved methods of treatment for hypertension.
Due to rising unhealthy lifestyle patterns, North America dominated the market in 2016. High blood pressure, smoking, diabetes, high levels of blood cholesterol, sedentary lifestyles, and lack of exercise are the primary risk factors for stroke among U.S. citizens. Increasing pressure to monitor stroke rates has therefore given market growth a significant boost.
Due to an increase in the geriatric population, Europe retained a significant market share in 2016. Stroke is the Europeans ' second most common cause of death. This caused around 433,000 deaths in 2013 in the European Union (EU). Approximately 152,000 stroke cases are registered a year in the UK, the Stroke Association states. As a result, increasing numbers of patients are expected to drive the region's demand for stroke diagnostic items.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the stroke diagnostics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in North America and Europe Stroke Diagnostics market.
The comprehensive market report features companies such as Boston Scientific Corp., Cordis Corporation, GE Healthcare, Hitachi Medical Systems, Neusoft Medical Systems, Philips Healthcare, Siemens Healthcare, Toshiba Medical Systems Corporation, Medtronic, Stryker, Merck Sharp & Dohme Corp., Teleflex Incorporated, B. Braun Melsungen AG, AliveCor, Inc., among other prominent players. Also, the research study offers market estimation and forecast for the period ranging from 2020-2030 for markets such as North America and Europe along with regional sub-markets as U.S., Canada, Germany, UK, France, Italy, Spain, Russia.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.